Medical imaging device firm Positrigo of Zurich, Switzerland, has secured clearance from the U.S. Food and Drug Administration (FDA) for its dedicated brain PET imaging system, NeuroLF.
The device helps diagnose and monitor brain disorders such as Alzheimer's disease, tumors, epilepsy, and Parkinson's disease. It allows patients to undergo a brain scan in a seated position, Positrigo said.
The company expects regulatory approval for the European market later this year.
